No clinically relevant differences in systemic absorption were observed, with peak plasma concentrations in the range of 2. The plasma elimination half-life of diclofenac after application of Flector Patch is approximately 12 hours. Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites.
In the first of these two studies, patients with ankle sprains were treated once daily for a week. In the second study, patients with sprains, strains and contusions were treated twice daily for up to two weeks. Pain was assessed over the period of treatment. Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular CV thrombotic events, myocardial infarction, and stroke, which can be fatal.
Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use.
Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy.
However, even short-term therapy is not without risk. NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status.
Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population. To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected.
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.
In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Emergency help should be sought in cases where an anaphylactoid reaction occurs.
These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. Abrupt discontinuation of corticosteroids may lead to disease exacerbation.
Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.
If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur e. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients with asthma may have aspirin-sensitive asthma.
The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. If eye contact occurs, immediately wash out the eye with water or saline. Consult a physician if irritation persists for more than an hour.
Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms.
Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms including epigastric pain, dyspepsia, melena, and hematemesis.
Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and should ask for medical advice when observing any indicative signs or symptoms.
Patients should be advised to stop the drug immediately if they develop any type of rash and contact their physicians as soon as possible. Patients should be informed of the warning signs and symptoms of hepatotoxicity e.
Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Results First Posted : May 11, Last Update Posted : May 11, Study Description.
The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch.
Drug Information available for: Diclofenac sodium Diclofenac potassium Diclofenac Diclofenac epolamine. FDA Resources. Arms and Interventions. Generic intrusion likely by will depress demand for Skelaxin, too, in coming quarters. With little visible success in the development of a longer-acting formulation, King has shifted promotional efforts of its person sales force to pain-relief products with more promising growth prospects, such as the non-steroidal anti-inflammatory NSAID Flector Patch and Embeda, the first of the new abuse-deterrent opioids to reach the U.
The Flector Patch is a noticeable bright spot in an otherwise troubled pain management franchise. Indicated for the topical treatment of acute pain due to minor sprains, strains, and contusions, the patch conveniently delivers prescription-strength NSAID analgesic relief diclofenac with a reduced incidence of GI distress oft-seen with oral NSAIDs, like ibuprofen Motrin and naproxen Naprosyn. Monthly total new prescriptions rose almost 58 percent from a reported 60, in the prior year period, according to chief executive Markison.
Morphine, oxycodone, and oxymorphone -- different chemical compounds that all share a common mechanism of action -- the binding to opioid receptors to decrease the perception of pain. Notwithstanding dosage forms, frequency of dosing, or method of delivery, these long-acting opioids LAO have become the standard of care for managing moderate-to-severe chronic pain.
Although U. Primary care physicians and pain experts interviewed by industry researcher Decision Resources affirmed that an important unmet clinical need in the treatment of chronic pain was for effective therapies that carried a lower risk of tolerance and dependence than opioid analgesics.
0コメント